Physician profile
Kenneth Goolsby
NPI 1366457012
$7,016.03
in general payments reported to CMS, 2019-2025
30 companies · $1,079 in 2025
The $1,079 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $723 · 2021: $1,145 · 2022: $1,248 · 2023: $1,006 · 2024: $922 · 2025: $1,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,007.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $722.15 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $690.31 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $616.65 | 2019-2025 | Spravato, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $605.70 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $521.58 | 2020-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $413.64 | 2021-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $392.85 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $357.98 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $303.06 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $269.93 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Allergan, INC. | $265.16 | 2019-2020 | |
| Corium, LLC | $255.07 | 2022-2025 | Azstarys |
| Alkermes, INC. | $201.68 | 2021-2023 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $199.18 | 2024-2025 | Auvelity |
| Lundbeck LLC | $188.84 | 2019-2025 | Rexulti, Abilify Maintena |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $164.25 | 2019-2024 | Sublocade |
| Idorsia Pharmaceuticals US INC | $105.31 | 2022-2024 | Quviviq |
| Eisai INC. | $99.99 | 2020-2022 | |
| Tris Pharma INC | $92.94 | 2023-2025 | Dyanavel Xr |
| Noven Therapeutics, LLC | $79.82 | 2023-2025 | Secuado, Xelstrym |
| Merck Sharp & Dohme LLC | $78.97 | 2020-2022 | |
| Bausch Health US, LLC | $75.70 | 2021-2025 | Wellbutrin, Aplenzin |
| Adlon Therapeutics L.P. | $72.43 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $72.16 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $63.90 | 2021 | |
| Neos Therapeutics, LP | $49.18 | 2024-2025 | Adzenys Xr-Odt, Exxua |
| E.R. Squibb & Sons, L.L.C. | $18.93 | 2024 | Cobenfy |
| Biodelivery Sciences International, INC. | $15.00 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.79 | 2020 | |
| Brainsway USA INC | $10.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Goolsby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.